A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
Study CXL-1020-02 employs is designed to further define suitable clinical dosages for
CXL-1020 which will be utilized in a later Phase IIb study. The study is conducted in 3
different stages called 'strata" and evaluates the potential utility of this drug for the
treatment of patents who are hospitalized with heart failure.